← Back to Search

Enhanced Quitline Support for Smoking Cessation (CONNECT Trial)

N/A
Waitlist Available
Led By Steffani Bailey
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up years 1-4
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether an online referral system for quitting smoking, with extra support to doctors, will help patients in community health centers quit smoking.

Who is the study for?
This trial is for adult tobacco users (18+) who have visited eligible study clinics in Oregon during a 24-month period. Participants must be willing to recruit a clinic champion and manager, agree to randomization, and their clinic should use the OCHIN Epic EHR system for at least one year.
What is being tested?
The trial tests an electronic Quitline referral system with enhanced academic detailing to see if it helps more people quit smoking. It compares how effective this strategy is against usual care in community health centers, also looking into its cost-effectiveness.
What are the potential side effects?
Since this trial involves informational interventions rather than medications or medical procedures, traditional side effects are not expected. However, participants may experience stress or discomfort related to quitting smoking.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~years 1-4
This trial's timeline: 3 weeks for screening, Varies for treatment, and years 1-4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Accepted electronic (e)Referral to Quitline
Secondary study objectives
Annual intervention costs
Cost-effectiveness
Incremental cost-effectiveness ratio
+5 more
Other study objectives
Tobacco use assessed

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ARM II (Quitline eReferral plus enhanced AD)Experimental Treatment2 Interventions
Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
Group II: Arm I (Quitline eReferral)Active Control1 Intervention
Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityOTHER
1,006 Previous Clinical Trials
7,404,112 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,013,170 Total Patients Enrolled
OHSU Knight Cancer InstituteLead Sponsor
236 Previous Clinical Trials
2,079,580 Total Patients Enrolled
Kaiser PermanenteOTHER
554 Previous Clinical Trials
27,721,754 Total Patients Enrolled
OCHIN, Inc.OTHER
22 Previous Clinical Trials
8,715,125 Total Patients Enrolled
Steffani BaileyPrincipal InvestigatorOHSU Department of Family Medicine

Media Library

Enhanced Academic Detailing Clinical Trial Eligibility Overview. Trial Name: NCT04969978 — N/A
Smoking Cessation Research Study Groups: Arm I (Quitline eReferral), ARM II (Quitline eReferral plus enhanced AD)
Smoking Cessation Clinical Trial 2023: Enhanced Academic Detailing Highlights & Side Effects. Trial Name: NCT04969978 — N/A
Enhanced Academic Detailing 2023 Treatment Timeline for Medical Study. Trial Name: NCT04969978 — N/A
~4000 spots leftby Dec 2025